Document:

EX-10.14

 Exhibit 10.14 

September 3, 2019 
 Herbert “Skip” Virgin IV, MD, PhD

 Dear Skip, 
 This letter agreement (the
“Agreement”) sets forth the terms and conditions of your continued employment with Vir Biotechnology, Inc. (“VirBio” or the “Company”). This Agreement supersedes and replaces all prior written
employment agreements, offer letters, or oral promises regarding the subject matter herein, including, but not limited to, your initial October 14, 2017 offer letter agreement with the Company. 

1. Position; Location: You will continue to serve as the Company’s Executive Vice President, Research and Chief Scientific
Officer and will be responsible for all duties associated with that role, along with any other duties that are assigned to you from time to time by the Company’s Board of Directors or the Compensation Committee thereof, as determinations or
responsibilities may be delegated from the Board of Directors to the Compensation Committee (collectively, the “Board”) and any subsidiary companies as applicable. This position is full-time. As an exempt salaried employee,
you are expected to work the Company’s normal business hours as well as additional hours as required by the nature of your work assignments, and you will not be eligible for overtime compensation. You will continue to work out of
VirBio’s offices located at 499 Illinois Street, Suite 500, San Francisco, CA 94158. Of course, the Company may change your position, duties, and work location from time to time in its discretion. 

2. Reporting Relationship: You will continue to report directly to the Chief Executive Officer. 

3. CIIAA; Company Policies: You are required to continue to abide by your obligations under the Company’s standard
confidential information and inventions assignment agreement (the “CIIAA”), a signed copy of which is attached to this letter as Exhibit A. In addition, you must continue to comply with Company’s personnel
policies and procedures as they may be interpreted, adopted, revised or deleted from time to time in the Company’s sole discretion. 

4. Base Salary: You will continue to receive an annualized base salary of $621,000. Salary is subject to deductions for taxes
and other withholdings as required by law and is payable in accordance with VirBio’s payroll cycle. 
 5. Annual Bonus:
You will continue to be eligible for an annual (calendar year) discretionary bonus, with a target amount equal to 40% of your annual base salary, contingent upon achievement, in the Company’s sole discretion, of individual and Company
performance objectives established by the Company, as well as any other criteria the Company deems relevant. Annual bonus payments are also contingent upon, and calculated with reference to, the availability of sufficient funds as determined by the
Board. In addition, you acknowledge and agree that any annual bonus payment shall be calculated in a manner that takes into consideration amounts you receive in royalty payments relating to licensing fees paid by the Company to the Washington
University in St. Louis (“WUSL”), and you agree to provide the Company, upon request, with documentation of all such royalty payments you may receive from WUSL. To receive 

 
payment of any bonus, you must be employed by the Company at the time bonuses are paid. Any bonus is not earned until paid and will be paid on or before March 15 of the year following the
year for which the bonus is awarded. If your employment terminates for any reason prior to the payment date, you will not have earned, and will not be paid, any pro-rated bonus. 

6. Housing: It is a condition of your continued employment hereunder that you maintain a residence in the San Francisco area.
You will receive a housing allowance in the amount of $7,000 per month, subject to all applicable deductions and withholding, for each month you remain employed with the Company through February 1, 2021. For the avoidance of doubt, this
paragraph shall not be construed as to require you to sell any residence located outside of the San Francisco area. 
 7. Equity:
In addition to any equity awards previously granted to you, you shall continue to be eligible for further equity awards from time to time as determined by the Board in its sole discretion. All equity awards shall be governed in all respects by
the terms of the applicable written agreements and plan documents. 
 8. Benefits: During your employment, you shall continue
to be eligible to participate in the employee benefit plans maintained by VirBio as are in effect from time to time and generally available to similarly situated VirBio employees, subject in each case to the generally applicable terms and conditions
of the plan in question and Company policies. In addition, you will continue to be eligible for paid time off consistent with applicable law and the VirBio policy generally applicable to similarly situated VirBio employees. Any benefits offered by
VirBio are subject to change without notice at the sole discretion of VirBio. 
 9.
At-Will Employment. Your employment with VirBio will continue to be at at-will, such that either you or the Company can terminate the relationship at any time
with or without cause and with or without notice; provided, however, that in the event you elect to terminate your employment without Good Reason (as defined in the Severance Plan referenced in Section 10 below), you agree to provide the
Company with at least thirty (30) days’ advance written notice. Your employment at-will status can only be modified in a written agreement signed by you and by an officer of the Company. 

10. Severance. You are eligible for severance benefits pursuant to the Company’s Change in Control and Severance Benefit
Plan, as approved by the Board on March 11, 2019, and as may be amended from time to time in the Company and Board’s sole discretion (the “Severance Plan”). You hereby acknowledge and agree that any prior written or oral
promise of severance benefits are hereby extinguished and superseded by your rights pursuant to the Severance Plan. 
 11.
Conflicts. By signing this letter, you are representing that you have full authority to accept this position and perform the duties of the position without conflict with any other obligations and that you are not involved in any situation
that might create, or appear to create, a conflict of interest with respect to your loyalty to or duties for the Company. You agree that while employed by the Company you will not engage in any other employment, consulting or other business that
would interfere with your duties to the Company or create a conflict of interest. You specifically warrant that you are not subject to an employment agreement or 

 
restrictive covenant preventing full performance of your duties to the Company. You agree not to bring to the Company or use in the performance of your responsibilities at the Company any
materials or documents of a former employer that are not generally available to the public, unless you have obtained express written authorization from the former employer for their possession and use. You also agree to honor all obligations to
former employers during your employment with The Company. 
 12. Outside Activities. You agree to devote such of your business
time, energy, and skill to the affairs of the Company and its subsidiaries as shall be necessary to perform the duties of such positions; provided, however, that you may engage in civic and not-for-profit activities (e.g. charitable and industry association activities) so long as such activities do not materially interfere with your obligations to the Company or create a conflict of interest.
You further agree that if, during the term of your relationship with the Company, you wish to perform any consulting or outside activities for any business or for-profit entities, including serving on any
advisory boards or boards of director of for-profit entities, any such additional activities shall require the Company’s prior written consent. You are hereby expressly permitted to engage in the
activities set forth in Exhibit B hereto, solely to the extent specified therein (collectively, the “Outside Activities”). It is agreed and understood that, so long as you devote sufficient time, energy, and skills to
your duties to the Company, maintain your confidentiality obligations to the Company and do not use or access any resources or facilities of the Company in connection with the performance of such Outside Activities, (i) your performance of such
Outside Activities as specifically set forth in Exhibit B and any assignment of intellectual property arising from such Outside Activities shall not be deemed a violation of this Agreement, your CIIAA, or any other agreement between
you and the Company; and (ii) your performance of the Outside Activities shall not be deemed a violation of any fiduciary duty owed to the Company. Notwithstanding the foregoing, the Company retains the right to revoke, in its sole discretion,
its consent to your engaging in any such Outside Activities, or to modify the scope of any Outside Activities you may perform for or in relation to any individual, organization or entity, including those set forth on Exhibit B. Any
such revocation or amendment of scope will be communicated to you in writing, and will be deemed effective as of the date of delivery of such notice of revocation. 

13. Dispute Resolution. To ensure the rapid and economical resolution of disputes that may arise in connection with your
employment with the Company, you and the Company agree that any and all disputes, claims, or causes of action, in law or equity, including but not limited to statutory claims, arising from or relating to the enforcement, breach, performance, or
interpretation of this Agreement, your employment with the Company, or the termination of your employment, shall be resolved pursuant to the Federal Arbitration Act, 9 U.S.C. § 1-16, to the fullest extent
permitted by law, by final, binding and confidential arbitration conducted by JAMS or its successor, under JAMS’ then applicable rules and procedures for employment disputes before a single arbitrator (available upon request and also currently
available at http://www.jamsadr.com/rules-employment-arbitration/). You acknowledge that by agreeing to this arbitration procedure, both you and the Company waive the right to resolve any such dispute through a trial by jury or judge or
administrative proceeding. In addition, all claims, disputes, or causes of action under this section, whether by you or the Company, must be brought in an individual capacity, and shall not be brought as a plaintiff (or claimant) or class member
in any purported class or representative proceeding, nor joined or consolidated with the claims of any other person or entity. The arbitrator may not consolidate the claims of more than one person or entity, and may not preside over any form of
representative 

 
or class proceeding. To the extent that the preceding sentences regarding class claims or proceedings are found to violate applicable law or are otherwise found unenforceable, any claim(s)
alleged or brought on behalf of a class shall proceed in a court of law rather than by arbitration. This paragraph shall not apply to any action or claim that cannot be subject to mandatory arbitration as a matter of law, including, without
limitation, claims brought pursuant to the California Private Attorneys General Act of 2004, as amended, to the extent such claims are not permitted by applicable law to be submitted to mandatory arbitration (collectively, the “Excluded
Claims”). In the event you intend to bring multiple claims, including one of the Excluded Claims listed above, the Excluded Claims may be publicly filed with a court, while any other claims will remain subject to mandatory arbitration. You
will have the right to be represented by legal counsel at any arbitration proceeding. Questions of whether a claim is subject to arbitration under this agreement shall be decided by the arbitrator. Likewise, procedural questions which grow out of
the dispute and bear on the final disposition are also matters for the arbitrator. The arbitrator shall: (a) have the authority to compel adequate discovery for the resolution of the dispute and to award such relief as would otherwise be
permitted by law; and (b) issue a written statement signed by the arbitrator regarding the disposition of each claim and the relief, if any, awarded as to each claim, the reasons for the award, and the arbitrator’s essential findings and
conclusions on which the award is based. The arbitrator shall be authorized to award all relief that you or the Company would be entitled to seek in a court of law. The Company shall pay all JAMS arbitration fees in excess of the administrative fees
that you would be required to pay if the dispute were decided in a court of law. Nothing in this letter agreement is intended to prevent either you or the Company from obtaining injunctive relief in court to prevent irreparable harm pending the
conclusion of any such arbitration. Any awards or orders in such arbitrations may be entered and enforced as judgments in the federal and state courts of any competent jurisdiction. 

14. Tax: All amounts payable under this letter are subject to all applicable deductions and withholding. 

15. Section 409A. To the extent that any provision of this offer is ambiguous as to its exemption or compliance with
Section 409A of the Internal Revenue Code of 1986, as amended, the provision will be read in such a manner so that all payments hereunder are exempt from Section 409A to the maximum permissible extent, and for any payments where such
construction is not tenable, that those payments comply with Section 409A to the maximum permissible extent. To the extent any payment under this offer may be classified as a “short-term deferral” within the meaning of
Section 409A, such payment will be deemed a short-term deferral, even if it may also qualify for an exemption from Section 409A under another provision of Section 409A. Payments pursuant to this offer (or referenced in this offer) are
intended to constitute separate payments for purposes of Section 1.409A-2(b)(2) of the regulations under Section 409A. 

16. Miscellaneous. This Agreement, together with your CIIAA, the Severance Plan, and any documentation related to your equity
interests, forms the complete and exclusive statement of your employment agreement with the Company. It supersedes any other agreements or promises made to you by anyone, whether oral or written. No term or provision of this Agreement may be amended
waived, released, discharged or modified except in writing, signed by you and an authorized officer of the Company, except that the Company may, in its sole discretion, adjust salaries, incentive compensation, stock plans, benefits, job titles,
locations, duties, responsibilities, and reporting relationships. This Agreement will be governed by the laws of 

 
California. If any provision of this Agreement is determined to be invalid or unenforceable, in whole or in part, this determination shall not affect any other provision of this offer letter
agreement and the provision in question shall be modified so as to be rendered enforceable in a manner consistent with the intent of the parties insofar as possible under applicable law. This Agreement may be delivered and executed via facsimile,
electronic mail (including pdf or any electronic signature complying with the U.S. federal ESIGN Act of 2000, Uniform Electronic Transactions Act or other applicable law) or other transmission method and shall be deemed to have been duly and validly
delivered and executed and be valid and effective for all purposes.  
 If you are in agreement with the terms set forth above,
please sign below and return the signed Agreement. 
  

	
	/s/ George Scangos
	 George Scangos
 Chief Executive
Officer

 Understood and Accepted: 

 

					
	/s/ Herbert Virgin	 		 	September 3, 2019
	Herbert “Skip” Virgin IV, MD, PhD	 		 	Date

 Exhibit A – CIIAA  

Exhibit B – Outside Activities 

 EXHIBIT A 

 EXHIBIT B 

OUTSIDE ACTIVITIESEX-10.15

 Exhibit 10.15 

VIR BIOTECHNOLOGY, INC. 

CHANGE IN CONTROL AND SEVERANCE BENEFIT
PLAN 
 APPROVED BY THE BOARD OF
DIRECTORS: MARCH 11, 2019 
 Section 1. INTRODUCTION. 

The Vir Biotechnology, Inc. Change in Control and Severance Benefit Plan (the “Plan”) is hereby established effective
March 11, 2019 (the “Effective Date”). The purpose of the Plan is to provide for the payment of severance benefits to eligible employees of Vir Biotechnology, Inc. (the “Company”) in
the event that such employees become subject to involuntary employment terminations, including in connection with a Change in Control. Except as otherwise provided in an individual Participation Agreement, this Plan shall supersede any severance
benefit plan, policy or practice previously maintained by the Company, including any severance benefits set forth in any individually negotiated employment contract or agreement between the Company and any eligible employee. This Plan document also
is the Summary Plan Description for the Plan. 
 For purposes of the Plan, the following terms are defined as follows: 

(a) “Affiliate” means any corporation (other than the Company) in an “unbroken chain of corporations”
beginning with the Company, if each of the corporations other than the last corporation in the unbroken chain owns stock possessing fifty percent (50%) or more of the total combined voting power of all classes of stock in one of the other
corporations in such chain. 
 (b) “Base Salary” means base pay (excluding incentive pay, premium pay,
commissions, overtime, bonuses and other forms of variable compensation) as in effect immediately prior to a Covered Termination and prior to any reduction that would give rise to an employee’s right to resign for Good Reason. 

(c) “Board” means the Board of Directors of the Company; provided, however, that if the Board has delegated
authority to administer the Plan to the Compensation Committee of the Board, then “Board” shall also mean the Compensation Committee. 

(d) “Cause” means, with respect to a particular employee, the occurrence of any of the following events:
(i) the employee’s commission of any felony or any crime involving fraud, dishonesty or moral turpitude under the laws of the United States or any state thereof; (ii) the employee’s attempted commission of, or participation in, a
fraud or act of dishonesty against the Company; (iii) the employee’s intentional, material violation of any contract or agreement between the employee and the Company or of any statutory duty owed to the Company; (iv) the
employee’s unauthorized use or disclosure of the Company’s confidential information or trade secrets; or (v) the employee’s gross misconduct. The determination whether a termination is for Cause shall be made by the Plan
Administrator in its sole and exclusive judgment and discretion. 
 (e) “Change in Control”
means the occurrence, in a single transaction or in a series of related transactions, of any one or more of the following events: 
 (1)
Any Exchange Act Person becomes the owner, directly or indirectly, of securities of the Company representing more than fifty percent (50%) of the combined voting power of the Company’s then outstanding securities other than by virtue
of a merger, consolidation or similar transaction. Notwithstanding the foregoing, a Change in Control shall not be deemed to occur (i) on account of the acquisition of securities of the Company by any institutional investor, any affiliate
thereof or any other Exchange Act Person that acquires the Company’s securities in a transaction or series of related transactions that are primarily a private financing transaction for the Company or (ii) solely because

  
 1. 

 
the level of ownership held by any Exchange Act Person (the “Subject Person”) exceeds the designated percentage threshold of the outstanding voting securities as a result
of a repurchase or other acquisition of voting securities by the Company reducing the number of shares outstanding, provided that if a Change in Control would occur (but for the operation of this sentence) as a result of the acquisition of voting
securities by the Company, and after such share acquisition, the Subject Person becomes the owner of any additional voting securities that, assuming the repurchase or other acquisition had not occurred, increases the percentage of the then
outstanding voting securities owned by the Subject Person over the designated percentage threshold, then a Change in Control shall be deemed to occur; 

(2) There is consummated a merger, consolidation or similar transaction involving, directly or indirectly, the Company if, immediately
after the consummation of such merger, consolidation or similar transaction, the stockholders of the Company immediately prior thereto do not own, directly or indirectly, either (i) outstanding voting securities representing more than fifty
percent (50%) of the combined outstanding voting power of the surviving entity in such merger, consolidation or similar transaction or (ii) more than fifty percent (50%) of the combined outstanding voting power of the parent of the
surviving entity in such merger, consolidation or similar transaction; or 
 (3) There is consummated a sale, lease, license or other
disposition of all or substantially all of the consolidated assets of the Company and its subsidiaries, other than a sale, lease, license or other disposition of all or substantially all of the consolidated assets of the Company and its subsidiaries
to an entity, more than fifty percent (50%) of the combined voting power of the voting securities of which are owned by stockholders of the Company in substantially the same proportion as their ownership of the Company immediately prior to such
sale, lease, license or other disposition. 
 The term Change in Control shall not include a sale of assets, merger or other transaction
effected exclusively for the purpose of changing the domicile of the Company. 
 (f) “Change in Control
Period” means the period commencing upon the Closing of a Change in Control and ending twelve (12) months following the Closing of a Change in Control. 

(g) “Change in Control Termination” means an Involuntary Termination that occurs within the Change in Control
Period. For such purposes, if the events giving rise to an employee’s right to resign for Good Reason arise within the Change in Control Period, and the employee’s resignation occurs not later than thirty (30) days after the
expiration of the Cure Period (as defined below), such termination shall be a Change in Control Termination. 
 (h)
“Closing” means the initial closing of the Change in Control as defined in the definitive agreement executed in connection with the Change in Control. In the case of a series of transactions constituting a Change in
Control, “Closing” means the first closing that satisfies the threshold of the definition for a Change in Control. 
 (i)
“COBRA” means the Consolidated Omnibus Budget Reconciliation Act of 1985. 
 (j)
“Code” means the Internal Revenue Code of 1986, as amended. 
 (k) “Company” means
Vir Biotechnology, Inc. or, following a Change in Control, the surviving entity resulting from such event. 
 (l) “Covered
Termination” means a Regular Termination or a Change in Control Termination. 
 (m) “Director”
means a member of the Board. 

  
 2. 

 (n) “Eligible Employee” means an employee of the Company who
meets the requirements to be eligible to receive Plan benefits as set forth in Section 2. 
 (o) “Entity”
means a corporation, partnership, limited liability company or other entity. 
 (p) “Exchange Act” means the
Securities Exchange Act of 1934, as amended, and the rules and regulations promulgated thereunder. 
 (q) “Exchange Act
Person” means any natural person, Entity or “group” (within the meaning of Section 13(d) or 14(d) of the Exchange Act), except that “Exchange Act Person” will not include (i) the Company or any Subsidiary
of the Company, (ii) any employee benefit plan of the Company or any Subsidiary of the Company or any trustee or other fiduciary holding securities under an employee benefit plan of the Company or any Subsidiary of the Company, (iii) an
underwriter temporarily holding securities pursuant to a registered public offering of such securities, (iv) an Entity Owned, directly or indirectly, by the stockholders of the Company in substantially the same proportions as their Ownership of
stock of the Company; or (v) any natural person, Entity or “group” (within the meaning of Section 13(d) or 14(d) of the Exchange Act) that, as of the Effective Date, is the Owner, directly or indirectly, of securities of the
Company representing more than 50% of the combined voting power of the Company’s then outstanding securities. 
 (r)
“Good Reason” has the meaning set forth in Section 2(c)(1) below. 
 (s) “Involuntary
Termination” means a termination of employment that is due to: (1) a termination by the Company without Cause or (2) an employee’s resignation for Good Reason. 

(t) “Own,” “Owned,” “Owner,” “Ownership”
means a person or Entity will be deemed to “Own,” to have “Owned,” to be the “Owner” of, or to have acquired “Ownership” of securities if such person or Entity, directly or indirectly, through any contract,
arrangement, understanding, relationship or otherwise, has or shares voting power, which includes the power to vote or to direct the voting, with respect to such securities. 

(u) “Participation Agreement” means an agreement between an employee and the Company in substantially the form
of Appendix A attached hereto, which may include such other terms as the Board deems necessary or advisable in the administration of the Plan. 

(v) “Plan Administrator” means the Board, or a duly authorized committee thereof, prior to the Closing and the
Representative upon and following the Closing. 
 (w) “Representative” means one or more members of the Board
or other persons or entities designated by the Board prior to or in connection with a Change in Control that will have authority to administer and interpret the Plan upon and following the Closing as provided in Section 7(a). 

(x) “Regular Termination” means an Involuntary Termination that is not a Change in Control Termination. 

(y) “Subsidiary” means, with respect to the Company, (i) any corporation of which more than 50% of the
outstanding capital stock having ordinary voting power to elect a majority of the board of directors of such corporation (irrespective of whether, at the time, stock of any other class or classes of such corporation will have or might have voting
power by reason of the happening of any contingency) is at the time, directly or indirectly, Owned by the Company, and (ii) any partnership, limited liability company or other entity in which the Company has a direct or indirect interest
(whether in the form of voting or participation in profits or capital contribution) of more than 50%. 

  
 3. 

 (z) “Target Bonus” means with respect to an Eligible
Employee, if there is a cash bonus plan applicable to such Eligible Employee for the year in which such Covered Termination occurs (“Cash Bonus Plan”), the cash bonus payable to such Eligible Employee under such Cash Bonus
Plan as if all the applicable performance goals for such year were attained at a level of 100%. If no Cash Bonus Plan is in effect for the year in which such Covered Termination occurs, the Target Bonus Amount will be the target bonus, if any, in
such Eligible Employee’s then-effective employment agreement or offer letter with the Company, as if all of the applicable performance goals for such year were attained at a level of 100%. 

Section 2. ELIGIBILITY FOR BENEFITS. 

(a) Eligible Employee. An employee of the Company is eligible to participate in the Plan if (i) the employee is at the level of
Vice President or higher; (ii) the Plan Administrator has designated such employee as eligible to participate in the Plan by providing such person with a Participation Agreement; (iii) such employee has signed and returned such
Participation Agreement to the Company within the period specified therein; (iv) such employee’s employment with the Company terminates due to a Covered Termination; and (v) such employee meets the other Plan eligibility requirements
set forth in this Section 2. The determination of whether an employee is an Eligible Employee shall be made by the Plan Administrator, in its sole discretion, and such determination shall be binding and conclusive on all persons. 

(b) Release Requirement. In order to be eligible to receive benefits under the Plan, the employee also must execute a general waiver and
release in the form provided by the Company (the “Release”), within the applicable time period set forth therein, but in no event more than fifty (50) days following the date of the applicable Covered Termination, and
such Release must become effective in accordance with its terms. 
 (c) Exceptions to Benefit Entitlement. An employee who otherwise
is an Eligible Employee will not receive benefits under the Plan in the following circumstances, as determined by the Plan Administrator in its sole discretion: 

(1) The employee voluntarily terminates employment with the Company without Good Reason, or terminates employment due to the
employee’s death or disability. Voluntary terminations include, but are not limited to, resignation, retirement or failure to return from a leave of absence on the scheduled date. “Good Reason” for an employee’s resignation means
the occurrence of any of the following events, conditions or actions taken by the Company without Cause and without such employee’s consent: (i) a material reduction of such employee’s annual base salary, which is a reduction of at
least 20% of such employee’s base salary (unless pursuant to a salary reduction program applicable generally to the Company’s similarly situated employees); (ii) a material reduction in such employee’s authority, duties or
responsibilities; (iii) a relocation of such employee’s principal place of employment with the Company (or successor to the Company, if applicable) to a place that increases such employee’s
one-way commute by more than fifty (50) miles as compared to such employee’s then-current principal place of employment immediately prior to such relocation (excluding regular travel in the ordinary
course of business); provided that if such employee’s principal place of employment is his or her personal residence, this clause (iii) shall not apply; or (iv) a material breach by the Company of any material agreement between the
employee and the Company; provided, however, that in each case above, in order for the employee’s resignation to be deemed to have been for Good Reason, the employee must first give the Company written notice of the action or omission
giving rise to “Good Reason” within thirty (30) days after the first occurrence thereof; the Company must fail to reasonably cure such action or omission within thirty (30) days after receipt of such notice (the “Cure
Period”), and the employee’s resignation must be effective not later than thirty (30) days after the expiration of such Cure Period. 

  
 4. 

 (2) The employee voluntarily terminates employment with the Company in order to
accept employment with another entity that is wholly or partly owned (directly or indirectly) by the Company or an Affiliate. 
 (3)
The employee is offered an identical or substantially equivalent or comparable position with the Company or an Affiliate. For purposes of the foregoing, a “substantially equivalent or comparable position” is one that provides the
employee substantially the same level of responsibility and compensation and would not give rise to the employee’s right to resign for Good Reason. 

(4) The employee is offered immediate reemployment by a successor to the Company or an Affiliate or by a purchaser of the
Company’s assets, as the case may be, following a Change in Control and the terms of such reemployment would not give rise to the employee’s right to resign for Good Reason. For purposes of the foregoing, “immediate reemployment”
means that the employee’s employment with the successor to the Company or an Affiliate or the purchaser of its assets, as the case may be, results in uninterrupted employment such that the employee does not incur a lapse in pay or
benefits as a result of the change in ownership of the Company or the sale of its assets. 
 (5) The employee is rehired by the
Company or an Affiliate and recommences employment prior to the date benefits under the Plan are scheduled to commence. 
 Section 3.
AMOUNT OF BENEFIT. 
 (a) Tiers. Benefit amounts under this Plan will be determined
based on Tiers, as follows: 
 Tier 1 = CEO 

Tier 2 = Employees at or above the level of SVP (not including Tier 1) 

Tier 3 = Employees at the VP Level (not including Tier 1 or Tier 2) 

(b) Regular Termination. Subject to the terms of the Plan, including, without limitation, execution of the required Release within the
applicable time period set forth herein and provided that such Release becomes effective in accordance with its terms, an Eligible Employee shall receive the following severance benefits upon a Regular Termination: 

(1) Cash Severance Benefit. 

(i) The employee will be entitled to a lump sum cash severance payment which shall be payable within ten (10) business days
following the effective date of the Release for the applicable amount indicated below (such period of months, the “Severance Period”): 
  

			
	 Tier
	  	 Severance Period

	Tier 1	  	12 months
	Tier 2	  	9 months
	Tier 3	  	6 months

  
 5. 

 (ii) Tier 1 and 2 employees will additionally be entitled to a portion of such
employee’s Target Bonus, if any, established for the employee by the Board for the year in which the Regular Termination occurs, in an amount equal to the employee’s annual Target Bonus for such year, if any,
pro-rated for the number of days in which the employee provided services to the Company in the year in with the Regular Termination occurs, which shall be payable in a lump sum payment within ten
(10) business days following the effective date of the Release. For the avoidance of doubt, Tier 3 employees will not be eligible for this benefit. 

(2) Payment of Continued Group Health Plan Benefits. If the employee timely elects continued group health plan continuation
coverage under COBRA the Company shall pay the full amount the employee’s COBRA premiums, or shall provide coverage under any self-funded plan, on behalf of the employee for his or her continued coverage under the Company’s group health
plans, including coverage for the employee’s eligible dependents, for the Severance Period (the “COBRA Payment Period”). Upon the conclusion of such period of insurance premium payments made by the Company, or the
provision of coverage under a self-funded group health plan, the employee will be responsible for the entire payment of premiums (or payment for the cost of coverage) required under COBRA for the duration of the employee’s eligible COBRA
coverage period. For purposes of this Section, (i) references to COBRA shall be deemed to refer also to analogous provisions of state law and (ii) any applicable insurance premiums that are paid by the Company shall not include any amounts
payable by the employee under an Internal Revenue Code Section 125 health care reimbursement plan, which amounts, if any, are the employee’s sole responsibility. 

(c) Change in Control Termination. Subject to the terms of the Plan, including, without limitation, execution of the required Release
within the applicable time period set forth herein and provided that such Release becomes effective in accordance with its terms, an Eligible Employee shall receive the following severance benefits upon a Change in Control Termination. For the
avoidance of doubt, in no event shall an employee be entitled to benefits under both Section 3(b) and this Section 3(c). If the employee is eligible for severance benefits under both Section 3(b) and this Section 3(c), the
employee shall receive the benefits set forth in this 3(c) and such benefits shall be reduced by any benefits previously provided to the employee under Section 3(b). 

(1) Cash Severance Benefit. 

(i) The employee will receive the cash severance benefit described in Section 3(b)(1)(i) above, except that the Severance Period
will be the applicable number of months provided below, and a lump sum payment shall be made within ten (10) business days following the later of (i) the effective date of the Release, or (ii) the effective date of the Closing. 

 

			
	 Tier
	  	 Severance Period

	Tier 1	  	18 months
	Tier 2	  	12 months
	Tier 3	  	9 months

 (ii) In addition, Tier 1 and 2 employees will be entitled to a payment equal to the Target Bonus, if
any, established for the employee by the Board for the year in which the Change in Control Termination occurs multiplied by the applicable multiple provided below (the “Bonus Multiple”), which shall be payable in a lump sum
payment within ten (10) business days following the later of (i) the effective date of the Release, or (ii) the effective date of the Closing. For the avoidance of doubt, Tier 3 employees will not be eligible for this benefit. 

 

			
	 Tier
	  	Bonus Multiple
	Tier 1	  	1.5
	Tier 2	  	1

  
 6. 

 (2) Payment of Continued Group Health Plan Benefits. The employee will
receive the payment for continued group health plan benefits described in Section 3(b)(2) above, except that the COBRA Payment Period will be equal to the Severance Period applicable to a Change in Control Termination as set forth in
Section 3(c)(1)(i) above. 
 (3) Equity Vesting. Notwithstanding anything to the contrary set forth in the applicable
equity plans, the vesting and exercisability (if applicable) of all outstanding unvested time-based equity awards granted under the Company’s equity incentive plans that are held by the employee on the date of the Change in Control Termination
will be accelerated in full. With respect to any performance-based vesting equity award, such award shall continue to be governed in all respects by the terms of the applicable equity award documents. 

(d) Additional Benefits. Notwithstanding the foregoing, the Company may, in its sole discretion, provide benefits to employees or
consultants who are not Eligible Employees (“Non-Eligible Employees”) chosen by the Plan Administrator, in its sole discretion, and the provision of any such benefits to a Non-Eligible Employee shall in no way obligate the Company to provide such benefits to any other Non-Eligible Employee, even if similarly situated. If benefits under the Plan
are provided to a Non-Eligible Employee, references in the Plan to “Eligible Employee” (and similar references) shall be deemed to refer to such Non-Eligible
Employee. 
 (e) Certain Reductions. The Company, in its sole discretion, shall have the authority to reduce an Eligible
Employee’s severance benefits, in whole or in part, by any other severance benefits, pay and benefits provided during a period following written notice of a plant closing or mass layoff, pay and benefits in lieu of such notice, or other similar
benefits payable to the Eligible Employee by the Company or an Affiliate that become payable in connection with the Eligible Employee’s termination of employment pursuant to (i) any applicable legal requirement, including, without
limitation, the Worker Adjustment and Retraining Notification Act or any other similar state law, (ii) any individually negotiated employment contract or agreement or any other written employment or severance agreement with the Company, or
(iii) any Company policy or practice providing for the Eligible Employee to remain on the payroll for a limited period of time (not to exceed sixty (60) days) after being given notice of the termination of the Eligible Employee’s
employment, and the Plan Administrator shall so construe and implement the terms of the Plan. Any such reductions that the Company determines to make pursuant to this Section 3(e) shall be made such that any benefit under the Plan shall be
reduced solely by any similar type of benefit under such legal requirement, agreement, policy or practice (i.e., any cash severance benefits under the Plan shall be reduced solely by any cash payments or severance benefits under such legal
requirement, agreement, policy or practice, and any continued insurance benefits under the Plan shall be reduced solely by any continued insurance benefits under such legal requirement, agreement, policy or practice). The Company’s decision to
apply such reductions to the severance benefits of one Eligible Employee and the amount of such reductions shall in no way obligate the Company to apply the same reductions in the same amounts to the severance benefits of any other Eligible
Employee, even if similarly situated. In the Company’s sole discretion, such reductions may be applied on a retroactive basis, with severance benefits previously paid being re-characterized as payments
pursuant to the Company’s statutory obligation. 

  
 7. 

 (f) Parachute Payments. 

(1) Any provision of the Plan to the contrary notwithstanding, if any payment or benefit an Eligible Employee would receive from the
Company pursuant to the Plan or otherwise (“Payment”) would (i) constitute a “parachute payment” within the meaning of Section 280G of the Code, and (ii) but for this sentence, be subject to the
excise tax imposed by Section 4999 of the Code (the “Excise Tax”), then such Payment will be equal to the Reduced Amount (defined below). The “Reduced Amount” shall be either (x) the largest
portion of the Payment that would result in no portion of the Payment being subject to the Excise Tax or (y) the largest portion, up to and including the total, of the Payment, whichever amount, after taking into account all applicable federal,
state and local employment taxes, income taxes, and the Excise Tax (all computed at the highest applicable marginal rate), results in the Eligible Employee’s receipt, on an after-tax basis, of the greater
economic benefit notwithstanding that all or some portion of the Payment may be subject to the Excise Tax. If a reduction in payments or benefits constituting “parachute payments” is necessary so that the Payment equals the Reduced Amount,
reduction shall occur in the manner that results in the greatest economic benefit for the Eligible Employee. If more than one method of reduction will result in the same economic benefit, the items so reduced will be reduced pro rata. 

(2) In the event it is subsequently determined by the Internal Revenue Service that some portion of the Reduced Amount as determined
pursuant to clause (x) in the preceding paragraph is subject to the Excise Tax, the Eligible Employee agrees to promptly return to the Company a sufficient amount of the Payment so that no portion of the Reduced Amount is subject to the Excise
Tax. For the avoidance of doubt, if the Reduced Amount is determined pursuant to clause (y) in the preceding paragraph, the Eligible Employee will have no obligation to return any portion of the Payment pursuant to the preceding sentence. 

(3) Unless the Eligible Employee and the Company agree on an alternative accounting firm, at the Company’s election, the
accounting firm engaged by the Company for general tax compliance purposes as of the day prior to the effective date of the a change in ownership or control shall perform the foregoing calculations. If the accounting firm so engaged by the Company
is serving as accountant or auditor for the individual, entity or group effecting the change in ownership or control, the Company shall appoint a nationally recognized accounting firm to make the determinations required hereunder. The Company shall
bear all expenses with respect to the determinations by such accounting firm required to be made hereunder. 
 Section 4. RETURN
OF COMPANY PROPERTY. 
 An Eligible Employee will not be entitled to any severance benefit
under the Plan unless and until the Eligible Employee returns all Company Property. For this purpose, “Company Property” means all Company documents (and all copies thereof) and other Company property which the Eligible Employee had in his
or her possession at any time, including, but not limited to, Company files, notes, drawings, records, plans, forecasts, reports, studies, analyses, proposals, agreements, financial information, research and development information, sales and
marketing information, operational and personnel information, specifications, code, software, databases, computer-recorded information, tangible property and equipment (including, but not limited to, computers, facsimile machines, mobile telephones,
servers), credit cards, entry cards, identification badges and keys; and any materials of any kind which contain or embody any proprietary or confidential information of the Company (and all reproductions thereof in whole or in part). 

Section 5. TIME OF PAYMENT AND FORM OF
BENEFIT. 
 All severance payments under the Plan will be subject to applicable withholding for federal, state and local
taxes. If an Eligible Employee is indebted to the Company on his or her termination date, the Company reserves the right to offset any severance payments under the Plan by the amount of such indebtedness. All severance benefits provided under the
Plan are intended to satisfy the requirements for an exemption from application of Section 409A of the Code to the maximum extent that an exemption is available and any ambiguities herein shall be interpreted accordingly; provided, however,
that to the extent such an exemption is not available, the severance benefits provided under the Plan are intended to comply with the requirements of Section 409A to the extent necessary to avoid adverse personal tax consequences and any
ambiguities herein shall be interpreted accordingly. 

  
 8. 

 Notwithstanding anything to the contrary set forth herein, any payments and benefits
provided under the Plan that constitute “deferred compensation” within the meaning of Section 409A of the Code and the regulations and other guidance thereunder and any state law of similar effect (collectively
“Section 409A”) shall not commence in connection with an Eligible Employee’s termination of employment unless and until the Eligible Employee has also incurred a “separation from
service,” as such term is defined in Treasury Regulations Section 1.409A-1(h) (“Separation from Service”), unless the Company reasonably determines that such amounts may be
provided to the Eligible Employee without causing the Eligible Employee to incur the adverse personal tax consequences under Section 409A. 

It is intended that (i) each installment of any benefits payable under the Plan to an Eligible Employee be regarded as a separate
“payment” for purposes of Treasury Regulations Section 1.409A-2(b)(2)(i), (ii) all payments of any such benefits under the Plan satisfy, to the greatest extent possible, the exemptions from the
application of Section 409A provided under Treasury Regulations Sections 1.409A-1(b)(4) and 1.409A-1(b)(9)(iii), and (iii) any such benefits consisting of
COBRA premiums also satisfy, to the greatest extent possible, the exemption from the application of Section 409A provided under Treasury Regulations Section 1.409A-1(b)(9)(v). However, if the Company
determines that any such benefits payable under the Plan constitute “deferred compensation” under Section 409A and the Eligible Employee is a “specified employee” of the Company, as such term is defined in
Section 409A(a)(2)(B)(i), then, solely to the extent necessary to avoid the imposition of the adverse personal tax consequences under Section 409A, (A) the timing of such benefit payments shall be delayed until the earlier of
(1) the date that is six (6) months and one (1) day after the Eligible Employee’s Separation from Service and (2) the date of the Eligible Employee’s death (such applicable date, the “Delayed Initial Payment
Date”), and (B) the Company shall (1) pay the Eligible Employee a lump sum amount equal to the sum of the benefit payments that the Eligible Employee would otherwise have received through the Delayed Initial Payment Date if
the commencement of the payment of the benefits had not been delayed pursuant to this paragraph and (2) commence paying the balance, if any, of the benefits in accordance with the applicable payment schedule. 

In no event shall payment of any benefits under the Plan be made prior to an Eligible Employee’s termination date or prior to the
effective date of the Release. If the Company determines that any payments or benefits provided under the Plan constitute “deferred compensation” under Section 409A, and the Eligible Employee’s Separation from Service occurs at a
time during the calendar year when the Release could become effective in the calendar year following the calendar year in which the Eligible Employee’s Separation from Service occurs, then regardless of when the Release is returned to the
Company and becomes effective, the Release will not be deemed effective any earlier than the latest permitted effective date (the “Release Deadline”). If the Company determines that any payments or benefits provided under the
Plan constitute “deferred compensation” under Section 409A, then except to the extent that payments may be delayed until the Delayed Initial Payment Date pursuant to the preceding paragraph, on the first regular payroll date following
the effective date of an Eligible Employee’s Release, the Company shall (1) pay the Eligible Employee a lump sum amount equal to the sum of the benefit payments that the Eligible Employee would otherwise have received through such payroll
date but for the delay in payment related to the effectiveness of the Release and (2) commence paying the balance, if any, of the benefits in accordance with the applicable payment schedule. 

All severance payments under the Plan shall be subject to applicable withholding for federal, state and local taxes. If an Eligible Employee
is indebted to the Company at his or her termination date, the Company reserves the right to offset any severance payments under the Plan by the amount of such indebtedness.     

  
 9. 

 Section 6. REEMPLOYMENT. 

In the event of an Eligible Employee’s reemployment by the Company during the period of time in respect of which severance benefits
pursuant to the Plan have been paid, the Company, in its sole and absolute discretion, may require such Eligible Employee to repay to the Company all or a portion of such severance benefits as a condition of reemployment. 

Section 7. RIGHT TO INTERPRET AND ADMINISTER PLAN;
AMENDMENT AND TERMINATION. 
 (a) Interpretation and Administration. Prior to the
Closing, the Board, or a duly authorized committee thereof, shall be the Plan Administrator and shall have the exclusive discretion and authority to establish rules, forms, and procedures for the administration of the Plan and to construe and
interpret the Plan and to decide any and all questions of fact, interpretation, definition, computation or administration arising in connection with the operation of the Plan, including, but not limited to, the eligibility to participate in the Plan
and amount of benefits paid under the Plan. The rules, interpretations, computations and other actions of the Board shall be binding and conclusive on all persons. Upon and after the Closing, the Plan will be interpreted and administered in good
faith by the Representative who shall be the Plan Administrator during such period. All actions taken by the Representative in interpreting the terms of the Plan and administering the Plan upon and after the Closing will be final and binding on all
Eligible Employees. Any references in this Plan to the “Board” or “Plan Administrator” with respect to periods following the Closing shall mean the Representative. 

(b) Amendment. The Plan Administrator reserves the right to amend this Plan at any time; provided, however, that any amendment of
the Plan will not be effective as to a particular employee who is or may be adversely impacted by such amendment or termination and has an effective Participation Agreement without the written consent of such employee. Any action amending the Plan
shall be in writing and executed by the Company’s Chairman of the Board (prior to the Closing) or the Representative (following the Closing). 

(c) Termination. The Plan shall have an initial term of five (5) years from the date of Board approval of the Plan and shall
automatically renew for successive two (2) year terms thereafter unless notice of termination of the Plan is given to all participants at least six (6) months in advance of any such renewal date; provided, however, that no such
termination shall occur once a Change in Control Period has commenced. In addition, no such termination may materially impair the rights of an Eligible Employee whose Covered Termination occurred prior to such termination, without the written
consent of such Eligible Employee. 
 Section 8. NO IMPLIED EMPLOYMENT CONTRACT.

 The Plan shall not be deemed (i) to give any employee or other person any right to be retained in the employ of the Company
or (ii) to interfere with the right of the Company to discharge any employee or other person at any time, with or without cause, which right is hereby reserved. 

Section 9. LEGAL CONSTRUCTION. 

This Plan is intended to be governed by and shall be construed in accordance with the laws of the State of California (but not its conflicts of
law provisions). 

  
 10. 

 APPENDIX A 

VIR BIOTECHNOLOGY, INC. 

CHANGE IN CONTROL AND SEVERANCE BENEFIT
PLAN 
 PARTICIPATION AGREEMENT 

Name: ___________________ 
 Section 1.
ELIGIBILITY. 
 You have been designated as eligible to participate in the Vir Biotechnology, Inc. Change in Control and
Severance Benefit Plan (the “Plan”), a copy of which is attached to this Participation Agreement (the “Agreement”). Capitalized terms not explicitly defined in this Agreement but defined in the Plan
shall have the same definitions as in the Plan. 
 Section 2. SEVERANCE BENEFITS 

Subject to the terms of the Plan, if you experience a Covered Termination, and meet all the other eligibility requirements set forth in the
Plan, including, without limitation, executing the required Release within the applicable time period set forth therein and provided that such Release becomes effective in accordance with its terms, you will receive the applicable severance benefits
set forth in Section 3 of the Plan. 
 Section 3. REQUIREMENTS DURING SEVERANCE
PERIOD. 
 Your eligibility for and receipt of any severance benefits to which you may become entitled as described in
Section 2 above is expressly contingent upon your timely execution of an effective Release and your compliance with the terms and conditions of the provisions of the Confidential Information and Invention Assignment Agreement
between you and the Company, as may be amended from time to time (the “CIIAA”). Severance benefits under this Agreement shall immediately cease in the event of your violation of the provisions in this Section 3.

 Section 4. ACKNOWLEDGEMENTS. 

As a condition to participation in the Plan, you hereby acknowledge each of the following: 

(a) The severance benefits that may be provided to you under this Agreement are subject to all of the terms of the Plan which is
incorporated into and becomes part of this Agreement, including but not limited to the reductions under Section 3 of the Plan. 
 (b)
This Agreement and the Plan supersedes any severance benefit plan, policy or practice previously maintained by the Company that may have been applicable to you or any individually negotiated employment contract or agreement between you and the
Company. 
 (c) You may not sell, transfer, or otherwise assign or pledge your right to benefits under this Agreement and the Plan to
either your creditors or to your beneficiary, except to the extent permitted by the Plan Administrator if such action would not result in adverse tax consequences under Section 409A. 

  
 11. 

 To accept the terms of this Agreement and participate in the Plan, please sign and date this Agreement in
the space provided below and return it to Head of HR, no later than ten (10) days from the date first set forth below. 
  

			
	VIR BIOTECHNOLOGY, INC.
		
	By:	 	 
		
	Name:	 	 
		
	Title:	 	 
		
	Date:	 	 

  

					
	 	 		  	  

	Name	 	    	  	Date

  
 12.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00299-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00299-of-00352.parquet"}]]